State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 10037, China.
Stem Cell Res Ther. 2022 Jul 7;13(1):289. doi: 10.1186/s13287-022-02969-y.
Bone marrow cells (BMCs), especially mesenchymal stem cells (MSCs), have shown attractive application prospects in acute myocardial infarction (AMI). However, the weak efficacy becomes their main limitation in clinical translation. Based on the anti-inflammation and anti-apoptosis effects of a Chinese medicine-Tongxinluo (TXL), we aimed to explore the effects of TXL-pretreated MSCs (MSCs) in enhancing cardiac repair and further investigated the underlying mechanism.
MSCs or MSCs and the derived exosomes (MSCs-exo or MSCs-exo) were collected and injected into the infarct zone of rat hearts. In vivo, the anti-apoptotic and anti-inflammation effects, and cardiac functional and histological recovery were evaluated. In vitro, the apoptosis was evaluated by western blotting and flow cytometry. miRNA sequencing was utilized to identify the significant differentially expressed miRNAs between MSCs-exo and MSCs-exo, and the miRNA mimics and inhibitors were applied to explore the specific mechanism.
Compared to MSCs, MSCs enhanced cardiac repair with reduced cardiomyocytes apoptosis and inflammation at the early stage of AMI and significantly improved left ventricular ejection fraction (LVEF) with reduced infarct size in an exosome-dependent way. Similarly, MSCs-exo exerted superior therapeutic effects in anti-apoptosis and anti-inflammation, as well as improving LVEF and reducing infarct size compared to MSCs-exo. Further exosomal miRNA analysis demonstrated that miR-146a-5p was the candidate effector of the superior effects of MSCs-exo. Besides, miR-146a-5p targeted and decreased IRAK1, which inhibited the nuclear translocation of NF-κB p65 thus protecting H9C2 cells from hypoxia injury.
This study suggested that MSCs markedly facilitated cardiac repair via a new mechanism of the exosomal transfer of miR-146a-5p targeting IRAK1/NF-κB p65 pathway, which has great potential for clinical translation.
骨髓细胞(BMCs),特别是间充质干细胞(MSCs),在急性心肌梗死(AMI)中显示出有吸引力的应用前景。然而,疗效不佳是其在临床转化中的主要限制。基于中药-通心络(TXL)的抗炎和抗凋亡作用,我们旨在探讨 TXL 预处理的 MSC(MSCs)增强心脏修复的作用,并进一步研究其潜在机制。
收集 MSC 或 MSC 及其衍生的外泌体(MSCs-exo 或 MSCs-exo),并注射到大鼠心脏梗死区。在体内,评估抗凋亡和抗炎作用以及心脏功能和组织学恢复。在体外,通过 Western blot 和流式细胞术评估细胞凋亡。利用 miRNA 测序鉴定 MSCs-exo 和 MSCs-exo 之间差异表达的 miRNAs,应用 miRNA 模拟物和抑制剂探讨其具体机制。
与 MSC 相比,MSC 在 AMI 早期通过减少心肌细胞凋亡和炎症增强心脏修复,并通过外泌体依赖的方式显著改善左心室射血分数(LVEF),减少梗死面积。同样,MSCs-exo 在抗凋亡和抗炎、改善 LVEF 和减少梗死面积方面表现出优于 MSC-exo 的治疗效果。进一步的外泌体 miRNA 分析表明,miR-146a-5p 是 MSC-exo 优越效果的候选效应物。此外,miR-146a-5p 靶向并降低 IRAK1,抑制 NF-κB p65 的核转位,从而保护 H9C2 细胞免受缺氧损伤。
这项研究表明,MSC 通过外泌体转移 miR-146a-5p 靶向 IRAK1/NF-κB p65 通路的新机制显著促进心脏修复,具有很大的临床转化潜力。